Betahistine


Concise Prescribing Info
Indications/Uses
Meniere's disease.
Dosage/Direction for Use
Adult: PO For vertigo, tinnitus and hearing loss associated in patients with Meniere's disease: As betahistine dihydrochloride: Initial: 8-16 mg tid or 24 mg bid, adjusted according to individual response. Maintenance dose: 24-48 mg/day. Max: 48 mg/day. As betahistine mesilate: 6-12 mg tid.
Administration
May be taken with or without food.
Contraindications
Phaeochromocytoma.
Special Precautions
Patients with bronchial asthma, CV disease, active or history of peptic ulcer disease. Hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Rarely, ventricular extrasystoles, hypotension (including orthostatic hypotension), tachycardia. Gastrointestinal disorders: Nausea, dyspepsia. Rarely, vomiting, bloating, abdominal distension or pain. General disorders and administration site conditions: Rarely, fatigue, malaise. Immune system disorders: Hypersensitivity reactions (e.g. anaphylaxis). Rarely, urticaria. Nervous system disorders: Headache. Rarely, dizziness, convulsions, somnolence. Psychiatric disorders: Rarely, confusion, hallucination. Respiratory, thoracic and mediastinal disorders: Rarely, dyspnoea, bronchospasm. Skin and subcutaneous tissue disorders: Rarely, rash, pruritus. Vascular disorders: Rarely, vasodilation.
Drug Interactions
Serum concentration may be increased by MAOIs (e.g. selegiline). Therapeutic effects may be decreased by antihistamines. May decrease the bronchodilator effects of β2 agonists.
CIMS Class
ATC Classification
N07CA01 - betahistine ; Belongs to the class of antivertigo preparations.
Disclaimer: This information is independently developed by CIMS based on betahistine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in